Skip to Content
Merck
All Photos(1)

Documents

341220

Sigma-Aldrich

Exo1

A cell-permeable methylanthranilate analog that reversibly inhibits vesicular traffic from ER to Golgi in mammalian cells by inducing tubulation and collapsing of the Golgi membrane.

Synonym(s):

Exo1, 2-(4-Fluorobenzoylamino)methylbenzoate, 2-(4-Fluorobenzoylamino)benzoic Acid Methyl Ester, ER Export Inhibitor I

Sign Into View Organizational & Contract Pricing


About This Item

Empirical Formula (Hill Notation):
C15H12FNO3
CAS Number:
Molecular Weight:
273.26
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

Quality Level

Assay

≥95% (HPLC)

form

solid

manufacturer/tradename

Calbiochem®

storage condition

OK to freeze
protect from light

color

white

solubility

DMF: 25 mg/mL
DMSO: 25 mg/mL
ethanol: 5 mg/mL
methanol: 5 mg/mL

shipped in

ambient

storage temp.

2-8°C

InChI

1S/C15H12FNO3/c1-20-15(19)12-4-2-3-5-13(12)17-14(18)10-6-8-11(16)9-7-10/h2-9H,1H3,(H,17,18)

InChI key

KIAPWMKFHIKQOZ-UHFFFAOYSA-N

General description

A cell-permeable methylanthranilate analog that reversibly blocks vesicular traffic from the ER to the Golgi in mammalian cells (IC50 = 20 µM in BSC1 cells) by inducing tubulation and collapsing of the Golgi membrane and re-directing the traffic back to the ER. Acts as a potent and selective modifier of Golgi ARF1 GTPase activity. Unlike another membrane traffic inhibitor, Brefeldin A (BFA) (Cat. No. 203729), the effects appear to be limited to the Golgi, as no effects are detected on endocytic organelles, such as endosomes and trans-Golgi network (TGN). The inhibitory mechanism and target(s) appear to be different from those of BFA, thus making it a valuable alternative that complements BFA in membrane trafficking studies.
A cell-permeable methylanthranilate analog that reversibly inhibits vesicular traffic from ER to Golgi in mammalian cells (IC50 = 20 µM in BSC1 cells) by inducing tubulation and collapsing of the Golgi membrane and redirecting the traffic back to ER. Acts as a potent and selective modifier of Golgi ARF1 GTPase activity. Unlike another membrane traffic inhibitor Brefeldin A (BFA; Cat. No. 203729), its effect seems to be limited to Golgi, as no effect can be detected on endocytic organelles, such as endosomes and TGN (trans-Golgi network). Its inhibitory mechanism and target(s) appear to be quite different from those of BFA and thus serves as a valuable alternative that complements BFA in membrane traffic studies.

Biochem/physiol Actions

Cell permeable: yes
Primary Target
Golgi ARF1 GTPase
Product does not compete with ATP.
Reversible: yes
Target IC50: 20 µM inhibiting vesicular traffic from ER to Golgi in BSC1 cells

Packaging

Packaged under inert gas

Warning

Toxicity: Harmful (C)

Reconstitution

Following reconstitution, aliquot and freeze (-20°C). Stock solutions are stable for up to 3 months at -20°C.

Other Notes

Feng. Y., et al. 2003. Proc. Natl. Acad. Sci. USA100, 6469.

Legal Information

CALBIOCHEM is a registered trademark of Merck KGaA, Darmstadt, Germany

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point(F)

Not applicable

Flash Point(C)

Not applicable


Certificates of Analysis (COA)

Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Chi-Ling Chiang et al.
Nature communications, 14(1), 6692-6692 (2023-10-24)
Pancreatic ductal adenocarcinoma (PDAC) tumours carry multiple gene mutations and respond poorly to treatments. There is currently an unmet need for drug carriers that can deliver multiple gene cargoes to target high solid tumour burden like PDAC. Here, we report

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service